- Renal Denervation In The Real World: Practical Guidance For New Users
During this unique broadcast, Radcliffe Medical Education brings together a globally-renowned European and American faculty to share best practices on resistant hypertension and renal denervation (RDN). If you manage patients with resistant hypertension – whether you treat directly or regularly refer patients to hypertension specialist services – this expert guidance will distil the most important practical points on identifying candidates for RDN. The aims of this broadcast are to draw attention to the current scale of resistant hypertension in the hypertensive population and to impart a sound understanding on appropriate patient selection for RDN.
Prof Roland Schmieder (University Hospital Erlangen, DE) leads proceedings, and is joined by Prof Michel Burnier (University Hospital of Lausanne, CH), Prof Cara East (Texas A&M College of Medicine, US) and Prof Konstantinos Tsioufis (University of Athens, GR) for a series of insightful presentations, discussions and live Q&A.
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. This programme is supported by an unrestricted educational grant from Medtronic.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Renal Denervation in the Real World: Practical Guidance for New Users’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
This programme is intended to educate:
- Specialists engaged in treating hypertension
- General Practitioners
- General Cardiologists
The overall programme, 'Renal Denervation in the Real World: Practical Guidance for New Users' endeavours to best address the following learning objectives:
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials
|Part 1 | Session 1||Introduction and What Is the Place of RDN Today?||Roland Schmieder|
|Part 2 | Session 1||Practice-based Principles For the Future Use of Renal Denervation||Cara East|
|Part 3 | Session 1||What Can Be Expected on RDN in the Future?||Michel Burnier|
|Part 4 | Session 1 of 1||Discussion and Close||Michel Burnier Lale Tokgozoglu Cara East Roland Schmieder|
Introduction and What Is the Place of RDN Today?
Practice-based Principles For the Future Use of Renal Denervation
What Can Be Expected on RDN in the Future?
Discussion and Close
1.00 European Board for Accreditation in Cardiology (EBAC)
- 1.00 EBAC
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
- Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
- Assess the interrelationships linking diabetes, HF and CVD.
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
- 1.00 EBAC
- Describe the evidence to support the use of renal denervation as a treatment modality in patients with resistant hypertension
- Understand renal denervation and how effective it is as a treatment option
- Identify patients with resistant hypertension suitable for renal denervation
- 1.00 EBAC
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
- differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
- apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
- assess the interrelationships linking diabetes, HF and CVD;
- interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
- 1.00 (EBAC)
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
- 0.25 AMA PRA Category 1 Credit™
- Recall the efficacy and safety of existing HCM treatments
- Summarize results from ongoing trials with experimental treatments for HFrEF and HCM